AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Overview
USA - NASDAQ:AKTX - US00972G2075 - ADR
AKTX Key Statistics, Chart & Performance
The current stock price of AKTX is 1.11 USD. In the past month the price increased by 29.07%. In the past year, price decreased by -62.24%.
AKTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.77 | 388.63B | ||
| AMGN | AMGEN INC | 12.8 | 150.32B | ||
| GILD | GILEAD SCIENCES INC | 14.69 | 141.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.23 | 96.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.64 | 61.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.08B | ||
| ARGX | ARGENX SE - ADR | 78.72 | 44.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.76 | 39.21B | ||
| INSM | INSMED INC | N/A | 29.80B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 22.50B | ||
| BIIB | BIOGEN INC | 8.6 | 20.18B |
Related stock screener links
About AKTX
Company Profile
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Company Info
AKARI THERAPEUTICS PLC-ADR
22 Boston Wharf Road, Fl 7
Boston MASSACHUSETTS W1G 9RT US
CEO: Clive Richardson
Employees: 9
Phone: 16463500702
AKARI THERAPEUTICS PLC-ADR / AKTX FAQ
What is the stock price of AKARI THERAPEUTICS PLC-ADR today?
The current stock price of AKTX is 1.11 USD. The price increased by 45.96% in the last trading session.
What is the ticker symbol for AKARI THERAPEUTICS PLC-ADR stock?
The exchange symbol of AKARI THERAPEUTICS PLC-ADR is AKTX and it is listed on the Nasdaq exchange.
On which exchange is AKTX stock listed?
AKTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKARI THERAPEUTICS PLC-ADR stock?
8 analysts have analysed AKTX and the average price target is 4.62 USD. This implies a price increase of 316.57% is expected in the next year compared to the current price of 1.11. Check the AKARI THERAPEUTICS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKARI THERAPEUTICS PLC-ADR worth?
AKARI THERAPEUTICS PLC-ADR (AKTX) has a market capitalization of 36.20M USD. This makes AKTX a Nano Cap stock.
How many employees does AKARI THERAPEUTICS PLC-ADR have?
AKARI THERAPEUTICS PLC-ADR (AKTX) currently has 9 employees.
What are the support and resistance levels for AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
AKARI THERAPEUTICS PLC-ADR (AKTX) has a resistance level at 1.23. Check the full technical report for a detailed analysis of AKTX support and resistance levels.
Should I buy AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKTX, evaluating the profitability, health, valuation and growth aspects
- AKARI THERAPEUTICS PLC-ADR (AKTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKARI THERAPEUTICS PLC-ADR (AKTX) Sales and EPS estimates to see what analysts future expectations are.
- AKARI THERAPEUTICS PLC-ADR (AKTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKARI THERAPEUTICS PLC-ADR (AKTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Chart to make your own analysis
- AKARI THERAPEUTICS PLC-ADR (AKTX) Latest news and press-releases to stay up to date.
Does AKARI THERAPEUTICS PLC-ADR (AKTX) stock pay dividends?
AKTX does not pay a dividend.
When does AKARI THERAPEUTICS PLC-ADR (AKTX) report earnings?
AKARI THERAPEUTICS PLC-ADR (AKTX) will report earnings on 2025-11-17.
What is the Price/Earnings (PE) ratio of AKARI THERAPEUTICS PLC-ADR (AKTX)?
AKARI THERAPEUTICS PLC-ADR (AKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
What is the Short Interest ratio of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
The outstanding short interest for AKARI THERAPEUTICS PLC-ADR (AKTX) is 11.46% of its float. Check the ownership tab for more information on the AKTX short interest.
AKTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AKTX. When comparing the yearly performance of all stocks, AKTX is a bad performer in the overall market: 94.31% of all stocks are doing better.
AKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AKTX. AKTX has a bad profitability rating. Also its financial health evaluation is rather negative.
AKTX Financial Highlights
Over the last trailing twelve months AKTX reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.09% | ||
| ROE | -47.91% | ||
| Debt/Equity | 0.06 |
AKTX Forecast & Estimates
8 analysts have analysed AKTX and the average price target is 4.62 USD. This implies a price increase of 316.57% is expected in the next year compared to the current price of 1.11.